微小RNA介导的癌症中KRAS基因的调控
MicroRNA-mediated regulation of KRAS in cancer.
作者信息
Kim Minlee, Slack Frank J
机构信息
Department of Molecular, Cellular and Developmental Biology, Yale University, PO Box 208103, New Haven, CT, 06511, USA.
Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA, 02215, USA.
出版信息
J Hematol Oncol. 2014 Nov 30;7:84. doi: 10.1186/s13045-014-0084-2.
Abstract
While microRNAs (miRNAs) and the KRAS oncogene are known to be dysregulated in various cancers, little is known about the role of miRNAs in the regulation of KRAS in cancer. Here we review a selection of studies published in 2014 that have contributed to our understanding of the molecular mechanisms of KRAS regulation by miRNAs and the clinical relevance of sequence variants that may interfere with functional miRNA-mediated KRAS regulation.
摘要
虽然已知微小RNA（miRNA）和KRAS癌基因在多种癌症中表达失调，但关于miRNA在癌症中对KRAS调控作用的了解却很少。在此，我们回顾了2014年发表的一系列研究，这些研究有助于我们理解miRNA对KRAS调控的分子机制，以及可能干扰功能性miRNA介导的KRAS调控的序列变异的临床相关性。
相似文献
1
MicroRNA-mediated regulation of KRAS in cancer.微小RNA介导的癌症中KRAS基因的调控
J Hematol Oncol. 2014 Nov 30;7:84. doi: 10.1186/s13045-014-0084-2.
2
Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.靶向敲入 rs61764370 多态性不会影响 KRAS 表达，但会降低 let-7 水平。
Hum Mutat. 2014 Feb;35(2):208-14. doi: 10.1002/humu.22487. Epub 2013 Dec 27.
3
Human cell line model for cancer-associated KRAS noncoding SNP.癌症相关KRAS非编码单核苷酸多态性的人类细胞系模型
Hum Mutat. 2014 Feb;35(2):v. doi: 10.1002/humu.22404.
4
MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.微小RNA分析可预测抗表皮生长因子受体治疗的野生型KRAS和BRAF的化疗难治性转移性结直肠癌患者的生存率。
Cancer Genet. 2012 Nov;205(11):545-51. doi: 10.1016/j.cancergen.2012.08.003. Epub 2012 Oct 23.
5
MicroRNA profiling differentiates colorectal cancer according to KRAS status.MicroRNA 谱可根据 KRAS 状态区分结直肠癌。
Genes Chromosomes Cancer. 2012 Jan;51(1):1-9. doi: 10.1002/gcc.20925. Epub 2011 Sep 15.
6
Gene of the month: KRAS.本月基因：KRAS。
J Clin Pathol. 2013 Jul;66(7):548-50. doi: 10.1136/jclinpath-2013-201663. Epub 2013 Apr 27.
7
miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.miRNA-96 抑制 KRAS，作为抑癌基因在胰腺癌中发挥作用。
Cancer Res. 2010 Jul 15;70(14):6015-25. doi: 10.1158/0008-5472.CAN-09-4531. Epub 2010 Jul 7.
8
Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.肺癌和卵巢癌病例中 KRAS 基因 3'非翻译区的广泛序列变异。
Cell Cycle. 2014;13(6):1030-40. doi: 10.4161/cc.27941. Epub 2014 Feb 3.
9
A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.KRAS基因3'非翻译区中一个与let-7微小RNA互补位点的单核苷酸多态性增加了非小细胞肺癌的发病风险。
Cancer Res. 2008 Oct 15;68(20):8535-40. doi: 10.1158/0008-5472.CAN-08-2129.
10
Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.KRAS和BRAF中的伴随突变及剪接变体表明晚期结直肠癌中Ras/Raf信号通路存在复杂的扰动。
Gut. 2009 Sep;58(9):1234-41. doi: 10.1136/gut.2008.159137. Epub 2009 May 26.
引用本文的文献
1
Regulation of KRAS protein expression by miR-544a and KRAS-LCS6 polymorphism in wild-type KRAS sporadic colon adenocarcinoma.miR-544a 调控 KRAS 蛋白表达与 KRAS-LCS6 多态性在 KRAS 野生型散发性结肠腺癌中的作用。
Hum Cell. 2021 Sep;34(5):1455-1465. doi: 10.1007/s13577-021-00576-2. Epub 2021 Jul 7.
2
Epigenetic effects toward new insights as potential therapeutic target in B-thalassemia.表观遗传学效应为β地中海贫血潜在治疗靶点带来新见解。
J Genet Eng Biotechnol. 2021 Mar 31;19(1):51. doi: 10.1186/s43141-021-00138-x.
3
-associated microRNAs in colorectal cancer.结直肠癌中的相关微小RNA
Oncol Rev. 2020 Jul 9;14(2):454. doi: 10.4081/oncol.2020.454. eCollection 2020 Jul 6.
4
Complexity in regulating microRNA biogenesis in cancer.癌症中 miRNA 生物发生调控的复杂性。
Exp Biol Med (Maywood). 2020 Mar;245(5):395-401. doi: 10.1177/1535370220907314. Epub 2020 Feb 19.
5
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas.miR-181ab1 簇促进肺和胰腺中 KRAS 驱动的肿瘤发生和进展。
J Clin Invest. 2020 Apr 1;130(4):1879-1895. doi: 10.1172/JCI129012.
6
From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers.从基础研究到KRAS驱动型癌症治疗策略的新成果
Cancer Biol Med. 2019 Aug;16(3):435-461. doi: 10.20892/j.issn.2095-3941.2018.0530.
7
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.针对转移性结直肠癌中的 KRAS：当前策略和新出现的机会。
J Exp Clin Cancer Res. 2018 Mar 13;37(1):57. doi: 10.1186/s13046-018-0719-1.
8
Prostate cancer small non-coding RNA transcriptome in Arabs.阿拉伯人前列腺癌的小非编码 RNA 转录组。
J Transl Med. 2017 Dec 21;15(1):260. doi: 10.1186/s12967-017-1362-x.
9
MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention.微小 RNA 对胰腺癌中 K-Ras 的调控及治疗干预的机会。
Semin Cancer Biol. 2019 Feb;54:63-71. doi: 10.1016/j.semcancer.2017.11.020. Epub 2017 Dec 2.
10
miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS.微小RNA-181a通过靶向原癌基因KRAS减缓皮肤鳞状细胞癌的增殖。
PLoS One. 2017 Sep 20;12(9):e0185028. doi: 10.1371/journal.pone.0185028. eCollection 2017.
本文引用的文献
1
Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer.let-7结合位点内功能性多态性rs712与甲状腺乳头状癌风险之间的关联。
Med Oncol. 2014 Oct;31(10):221. doi: 10.1007/s12032-014-0221-3. Epub 2014 Sep 9.
2
The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.RTOG子宫内膜癌临床试验9708和9905中的KRAS变异与miRNA表达
PLoS One. 2014 Apr 14;9(4):e94167. doi: 10.1371/journal.pone.0094167. eCollection 2014.
3
Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).III期结肠癌中KRAS基因3'非翻译区let-7 miRNA互补位点变异的关联研究（NCCTG N0147临床试验）
Clin Cancer Res. 2014 Jun 15;20(12):3319-27. doi: 10.1158/1078-0432.CCR-14-0069. Epub 2014 Apr 11.
4
Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.肺癌和卵巢癌病例中 KRAS 基因 3'非翻译区的广泛序列变异。
Cell Cycle. 2014;13(6):1030-40. doi: 10.4161/cc.27941. Epub 2014 Feb 3.
5
Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.多种受体酪氨酸激酶作用于微小RNA-134，以调控KRAS、STAT5B和胶质母细胞瘤。
Cell Death Differ. 2014 May;21(5):720-34. doi: 10.1038/cdd.2013.196. Epub 2014 Jan 17.
6
Transcriptome-wide analysis of UTRs in non-small cell lung cancer reveals cancer-related genes with SNV-induced changes on RNA secondary structure and miRNA target sites.非小细胞肺癌中UTR的全转录组分析揭示了与癌症相关的基因，这些基因具有由单核苷酸变异（SNV）引起的RNA二级结构和miRNA靶位点变化。
PLoS One. 2014 Jan 8;9(1):e82699. doi: 10.1371/journal.pone.0082699. eCollection 2014.
7
miR-193b/365a cluster controls progression of epidermal squamous cell carcinoma.miR-193b/365a 簇控制表皮鳞状细胞癌的进展。
Carcinogenesis. 2014 May;35(5):1110-20. doi: 10.1093/carcin/bgt490. Epub 2013 Dec 28.
8
MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.MicroRNA-30b 通过靶向 KRAS、PIK3CD 和 BCL2 在人结直肠癌中发挥肿瘤抑制作用。
J Pathol. 2014 Mar;232(4):415-27. doi: 10.1002/path.4309.
9
A let-7 KRAS rs712 polymorphism increases colorectal cancer risk.一种let-7 KRAS基因rs712多态性增加结直肠癌风险。
Tumour Biol. 2014 Jan;35(1):831-5. doi: 10.1007/s13277-013-1114-3. Epub 2013 Aug 24.
10
EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.EVI1 癌基因通过抑制 microRNA-96 促进胰腺发生中的 KRAS 通路。
Oncogene. 2014 May 8;33(19):2454-63. doi: 10.1038/onc.2013.204. Epub 2013 Jun 10.
Zotero 插件